ENLIVEN THERAPEUTICS INC (ELVN)
Health Care · Oncology / BCR-ABL inhibitors for hematologic malignancies · NASDAQ
An early-stage biotech advancing ELVN-001, a novel BCR-ABL inhibitor, through clinical trials for chronic myeloid leukemia and related blood cancers.
What ENLIVEN THERAPEUTICS INC does
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies, primarily through its lead program ELVN-001. The company is advancing ELVN-001 through clinical trials for chronic myeloid leukemia (CML) and other hematologic malignancies. With a limited operating history and no approved products, the company is dedicating substantial resources to drug development, regulatory approval pathways, and eventual commercialization of its product candidates.
Themes: ["BCR-ABL inhibitors / chronic myeloid leukemia","Hematologic malignancies","Clinical-stage drug development","Oncology"]
Fundamentals
- Price$52.18 as of 2026-07-09 close
- Market cap$3.7B as of 2026-07-10
- 1-year return+154.9% as of 2026-07-09 close
- ROE-21.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.53 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on ELVN-001 success; failure to advance through clinical development or obtain regulatory approval would materially harm the business","No approved products or revenue history; company is pre-commercial and will require substantial additional capital to complete development and operate","Clinical trial outcomes are unpredictable; negative results or FDA disagreement on trial design could delay or prevent commercialization"]
Competitors & peers
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Incyte (INCY)
- Takeda Pharmaceutical (TKDY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.